

Prescriber Criteria Form  
 Krazati 2026 PA Fax 5702-A v1 010126.docx  
 Krazati (adagrasib)  
 Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.  
 Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**. Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Krazati (adagrasib).

Drug Name:  
Krazati (adagrasib)

**Patient Name:**

**Patient ID:**

Patient DOB:	Patient Phone:
--------------	----------------

**Prescriber Name:**

**Prescriber Address:**

City:	State:	Zip:
-------	--------	------

Prescriber Phone:	Prescriber Fax:
-------------------	-----------------

Diagnosis:	ICD Code(s):
------------	--------------

**Please circle the appropriate answer for each question.**

1	Does the patient have a diagnosis of central nervous system (CNS) brain metastases from KRAS G12C-positive non-small cell lung cancer (NSCLC)? [If yes, then no further questions.]	Yes	No
2	Does the patient have a diagnosis of non-small cell lung cancer (NSCLC)? [If no, then skip to question 6.]	Yes	No
3	Is the disease locally advanced, recurrent, or metastatic? [If no, then no further questions.]	Yes	No
4	Does the patient have a KRAS G12C mutation? [If no, then no further questions.]	Yes	No
5	Has the patient received at least one prior systemic therapy? [No further questions.]	Yes	No
6	Does the patient have a diagnosis of colorectal cancer (CRC)? [If no, then skip to question 9.]	Yes	No
7	Is the disease advanced or metastatic? [If no, then no further questions.]	Yes	No
8	Does the patient have a KRAS G12C mutation? [No further questions.]	Yes	No

9	Does the patient have any of the following diagnoses: A) pancreatic adenocarcinoma, B) ampullary adenocarcinoma, C) appendiceal adenocarcinoma, D) biliary tract cancer (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gall bladder cancer)? [If no, then no further questions.]	Yes	No
10	Does the patient have a KRAS G12C mutation?	Yes	No

Comments:	_____
-----------	-------

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.
---

Prescriber (or Authorized) Signature: _____	Date: _____
---	-------------